Posted inBiotechnology
Rickettsia felis-Inspired Meningoencephalitis in Child: Case Study
In a landmark case that has captivated the medical community, researchers have reported the occurrence of Rickettsia felis meningoencephalitis in…
Posted inBiotechnology
COMP Drives Colorectal Cancer via EMT Regulation
In the relentless quest to unravel the complexities of colorectal cancer (CRC), a groundbreaking study has spotlighted a pivotal molecular…
Posted inBiotechnology
Hypoxia’s Role in m6A Regulation in Liver Cancer
In the intricate realm of cancer biology, the role of epitranscriptomics—specifically the m^6A methylation of RNA—has emerged as a significant…
Posted inBiotechnology
Common Antibiotic Linked to Lower Schizophrenia Risk, New Study Reveals
In a groundbreaking stride toward mental health prevention, recent research suggests that doxycycline, a widely prescribed antibiotic, may play a…
Posted inBiotechnology
Novo drops oncology ambitions, early-stage MASH prospects in ongoing R&D shake-up
Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of…
Posted inBiotechnology
Lilly pulls out of CNS portion of $960M RIPK1 inhibitor collab with Rigel
Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on…
Posted inMedical Technology
Dexcom hit by FDA Class I recall for its continuous glucose monitoring system app
Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system…
Posted inBiotechnology
Novo Nordisk CEO ‘feels’ Danish pharma will bag Metsera at end of Pfizer bidding war
Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera…
Posted inBiotechnology
Co-electroreduction of CO and Glyoxal Yields C3 Products
In the relentless pursuit of sustainable chemical manufacturing, the electrochemical conversion of carbon dioxide (CO₂) and carbon monoxide (CO) into…
Posted inBiotechnology
FDA rejects Biohaven approval request for troriluzole, triggering R&D cost cutting
The FDA has rejected Biohaven’s request for approval of a neurological disorder therapy, prompting the biopharma to reprioritize its pipeline in…